Abbott (NYSE:ABT) today said it launched a new bundle with Withings for its Lingo over-the-counter glucose biosensor.
The globally available feature is finally rolling out in the US, but you'll need to buy extra hardware to use it.
Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026 US Patent and Trademark Office (USPTO) issued paten ...
StockStory.org on MSN
Winners and losers of Q4: Insulet (NASDAQ:PODD) vs the rest of the patient monitoring stocks
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including Insulet ...
Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026 ...
Around 1.2 million Australians live with type 2 diabetes, yet there is no government subsidy for CGMs, despite this being well-established ...
Glucotrack (Nasdaq:GCTK) today provided an update on the planned regulatory timeline for its continuous blood glucose monitor ...
Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization ...
Experience From Brazilian and Australian Clinical Trials Positions the Company to Submit Investigational Device Exemption (IDE) to FDA for Novel CBGM Technology in Q2 2026 ...
Until now. Backed by more than six years of dedicated research and development in biosensing technology, Ottai has released a ...
A trial testing new treatments aimed at restoring warning signs of low blood glucose in people with type 1 diabetes when ...
A University of Virginia Center for Diabetes Technology-developed algorithm – paired with a continuous glucose monitor – can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results